paired 18F-fluciclovine (FACBC) and 68Ga-PSMA-11 (PSMA) PET/CT scans for localizing prostate cancer (PCa) early biochemical recurrence (BCR) after radical prostatectomy (RP) (NCT02940262).
INTRODUCTION AND OBJECTIVES:
18 F-DCFPyL is a radiolabeled ligand binding to prostate specific membrane antigen (PSMA), a recognized target for prostate cancer PET imaging. Through a research access program, 18 F-DCFPyL PET/CT is available at our institution for patients with biochemical recurrent prostate cancer (BCR PC). We present our data from the use of 118F-DCFPyL in patients with BCR PC. We also show data from the comparison of F-DCFPyL PET/ CT-positivity rate was 82% (41 positive scans and 9 negative scans). Uptake in the prostate bed was noted in 15 scans, in lymph nodes in 27 scans, in the skeleton in 19 scans, and in other visceral sites such as the lung, the adrenal gland and liver in 8 scans. Positivity rates were 47% (7/15) for PSA<1ng/mL, 100% (4/4) for PSA 1-2 ng/mL, 90% (9/10) for PSA 2-5 ng/mL, and 100% (21/21) for PSA >5 ng/mL. Putative sites of disease were detected with PSA as low as 0.4 ng/mL. F DCFPyL PET/CT had similar performance to 18F NaF PET/CT for detecting bone metastases. Taken together, 18 F DCFPyL PET/CT may be used as a "one stop shop" for evaluation of patients with BCR PC. However, more patients have to be evaluated to support these findings.
Source of Funding: Prostate Cancer Foundation

LBA-23 SINGLE PORT RADICAL PROSTATECTOMY VERSUS XI MULTI-PORT RADICAL PROSTATECTOMY: A HUMAN FACTOR ANALYSIS
Susan Talamini*, Whitney Halgrimson, Ryan Dobbs, chicago, IL; Simone Crivellaro, Chicago, IL INTRODUCTION AND OBJECTIVES: Cognitive load measures the number of informational elements that need to be processed to complete a given task, previously it has been shown that increases in overall cognitive load can result in stress, decreased efficiency, and ultimately suboptimal surgeon performance. The da Vinci Single Port (SP) robotic platform (Intuitive Surgical, Sunnyvale, CA) is a novel technology which offers new capabilities to the urologic surgeon, but its impact on surgeon cognitive load and performance is unknown. To
